stem

When Volume Matters, Immunoassay Systems Deliver

Although new and innovative technology has enabled more and more laboratory testing to occur at the bedside or physicians office, the central laboratory is hardly threatened with extinction. National volume data suggest that medium and large labs are busier than ever before, and the huge range of their capabilities, gold standard reliability and ability to handle very large volumes of tests a...

Genetic Analysis Systems Enter the Clinical Mainstream

Like many other diagnostic regimes that were previously restricted to large specialty laboratories, genetic analysis is entering the clinical mainstream. Smaller, simpler analyzer systems are now suitable and affordable for hospital or large physicians group labs, while some genetic test kits are becoming available for primary point of care locations such as clinics and physician offices.<...

New Quality Control Systems for Every Laboratory Application

Quality Control (QC) materials and procedures are key to meeting the needs of doctors and patients by verifying accuracy and precision of analytical methods. Vendors of these systems can be a valuable resource, designing customized QC materials and protocols to help lab managers ensure that analytical error st...

Immunoassay Systems - Your Laboratory Workhorse

Although new and innovative technology has enabled more and more laboratory testing to occur at the bedside or physicians office, the central laboratory is hardly threatened with extinction. National volume data suggest that medium and large labs are busier than ever before, and the huge range of their capabilities, gold standard reliability and ability to handle very large volumes of tests a...

Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting System's Success in Mouse Model Reported in Cancer Cell

HOUSTON, July 9, 2007 - A molecularly engineeredtherapy selectively embeds a gene in pancreatic cancer that shrinksor eradicates tumors, inhibits metastasis, and prolongs survivalwith virtually no toxicity, researchers from The University ofTexas M. D. Anderson Cancer Center report in the July 9 edition ofCancer Cell. "This vehicle, or vector, is so targeted and robust in itscanc...

Researchers Discover Method for Identifying How Cancer Evades the Immune System

PHILADELPHIA, July 3, 2007-- One of the fundamental traits of atumor – how it avoids the immune system – might becomeits greatest vulnerability, according to researchers from theUniversity of Southern California. Their findings,demonstrated in human breast and colorectal cancers, indicate thata technique for determining a tumor’s “immunesignature,” could be...

Beike Biotechnology Study Suggests Adult Stem Cells Show Promise for Peripheral Vascular Disease

Adult stem cells cultivated from patients' own blood canpotentially improve the quality of life for patients whose lowerextremities are affected by peripheral vascular disease, accordingto a study in China. SHENZHEN, China, July 02, 2007 /PRNewswire/ -- BeikeBiotechnology Co., Ltd. (<a target="_blank" href="http://www.beikebiotech.com/">http://www.beikebiotech.com )today announced tha...

Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics

PHILADELPHIA, July 3, 2007 ? Researchers in Slovakia havebeen able to derive mesenchymal stem cells from human adipose, orfat, tissue and engineer them into “suicide genes” that seek out and destroy tumors like tiny homing missiles. This gene therapy approach is a novel way to attack smalltumor metastases that evade current detection techniques andtreatments, the researchers...

Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study

SYDNEY, Australia--(BUSINESS WIRE)--Jun 27, 2007 - PrimeCell(TM)Therapeutics LLC (http://www.primecelltherapeutics.com) todayannounced that it provided research support and pre-clinicalstudies for a clinical trial to assess the safety, feasibility andefficacy of implanting autologous bone marrow stem cells intospinal cord injury (SCI) patients. Dr. Luis Geffner presented a preliminary rep...

Bio-Matrix Scientific's Dr. O'Neill Sees University of Pittsburgh's Published Study on Culture Blood-Forming Stem Cells from Human Fat Tissue as Supporting Near Term Benefits of Banking Adipose (Fat) Derived Stem Cells

SAN DIEGO--(BUSINESS WIRE)--Jun 27, 2007 - The University ofPittsburgh School of Health Sciences issued the following study andpress release, "Scientists Culture Blood-Forming Stem Cells fromHuman Fat Tissue," June 15, 2007, Science Daily: "Researchers atthe University of Pittsburgh School of Medicine have successfullyisolated and cultured human hematopoietic stem cells from fat, oradipose...

Publication Confirms that EpCAM, the Target for Two of Micromet's Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers

BETHESDA, Md., June 26, 2007 /PRNewswire-FirstCall/ -- Micromet,Inc. , a biopharmaceutical company focusing on the development ofnovel, proprietary antibody-based products for cancer, inflammatoryand autoimmune diseases, announced that a study published recentlyin the Proceedings of the National Academy of Sciences (1) supportsthe findings of several other studies that EpCAM (CD326), whic...

Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos

New survey shows more than half of infertile couples willing todonate unused embryos for stem cell research BETHESDA, Md., June 20, 2007 /PRNewswire/ -- RESOLVE: TheNational Infertility Association issued the following statementtoday, in anticipation of President Bush's veto of federallegislation that would loosen current limitations on stem cellresearch: "President Bush is choosin...

Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries

WASHINGTON--(BUSINESS WIRE)--Jun 20, 2007 - Today, President BushSigned An Executive Order To Strengthen Our Nation's Commitment ToResearch On Pluripotent Stem Cells. Scientists have recently shownthey have the ingenuity and skill to pursue the potential benefitsof pluripotent stem cell research - research on cells that have thepotential to develop into nearly all the cell types and tissues...

President Bush Ignores America's Plea for Support of Stem Cell Research

WASHINGTON, June 20, 2007 /PRNewswire-USNewswire/ -- Thefollowing statement may be attributed to Sean Tipton, president,Coalition for the Advancement of Medical Research (CAMR): "In the face of spiraling health care costs, President Bush onceagain used the stroke of his veto pen deliberately to hamper theprogress of scientific and medical research, as well as endangerthe future hea...

The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bush's Veto of the Stem Cell Research Enhancement Act

SHORT HILLS, N.J., June 20, 2007 /PRNewswire-USNewswire/ -- TheChristopher and Dana Reeve Foundation (CDRF), the national,non-profit organization dedicated to finding cures and treatmentsfor spinal cord injuries and improving the lives of people livingwith paralysis, today expressed strong disappointment in PresidentBush's veto of the Stem Cell Research Enhancement Act, which wouldhave p...

Obama Statement on Bush Veto of Stem Cell Bill

CHICAGO--(BUSINESS WIRE)--Jun 20, 2007 - Senator Obama todayreleased the following statement in response to President Bush'sveto of Stem Cell Bill: "By vetoing funding for stem cell research once again, thePresident is deferring the hopes of millions of Americans who donot have the time to keep waiting for the cure that may save orextend their lives. The promise that stem cells hold does...

Remarks by President Bush on Stem Cell Veto and Executive Order

WASHINGTON, June 20, 2007 /PRNewswire-USNewswire/ -- Thefollowing is a transcript of remarks by President Bush on stem cellveto and executive order: THE PRESIDENT: Welcome. I'm glad you're here. America is anation that leads the world in science and technology. Ourinnovative spirit is making possible incredible advances inmedicine that could sa...

Apollo's human proteins boost stem cell research

SYDNEY, Australia, June 21, 2007-At a time when Australianscientists are fighting hard to keep pace with overseas researchand development, an Australian biotech company is leading the worldin the production of human proteins for stem cell research. Apollo CEO John Priest said the company's human proteins areunique in the way they help stem cells to develop into specificcell types s...

Pelosi: Bush Veto of Stem Cell Bill Says 'No' to the Hopes of Million of Families Across America

WASHINGTON, June 20, 2007 /PRNewswire-USNewswire/ -- SpeakerNancy Pelosi issued the following statement today in response toPresident Bush's veto of the stem cell bill: "Once again, the President has ignored the will of the Americanpeople, of leading medical researchers, and of a bipartisanmajority of the Congress. His cruel veto says 'no' to the hopes ofmillion of families across...

Advanced Cell Technology Develops First Human Embryonic Stem Cell Line without Destroying an Embryo

ALAMEDA, Calif.--(BUSINESS WIRE)--Jun 21, 2007 - Advanced CellTechnology, Inc. (OTCBB: ACTC) has successfully produced a humanembryonic stem cell (hESC) line without destroying an embryo at itslab in Worcester, Massachusetts. This development was announced byRobert Lanza, M.D., V.P. of Research and Scientific Development ofAdvanced Cell Technology (ACT) on Tuesday at the fifth annualmeeting...

Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Geron's Human Embryonic Stem Cell-Based Therapeutic for Heart Failure

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 19, 2007 - GeronCorporation (Nasdaq: GERN) today reported that research documentingthe scalable production, survival following engraftment andpositive impact on cardiac function in infarcted rats was presentedtoday for GRNCM1, the company's human embryonic stem cell(hESC)-based therapeutic for heart failure, at the InternationalSociety for Stem Cell...

Next Safety, Inc.'s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery

WEST JEFFERSON, N.C.--(BUSINESS WIRE)--Jun 15, 2007 - Next Safety,Inc. has identified basic scientific mechanisms that promise torevolutionize pulmonary drug delivery. This proprietary technologyuses a stream of purified air to deliver medications deep into thepulmonary system. It is considered superior to other drug deliverysystems because it rapidly administers aerosolized drugs to thelin...

Pluristem's PLX Cells Demonstrate Potential to Treat Parkinson's Disease

NEW YORK--(BUSINESS WIRE)--Jun 14, 2007 - Pluristem Life Systems,Inc. (OTCBB:PLRS) (DAX:PJT), a bio-therapeutics Company dedicatedto the commercialization of products for a variety of malignant,degenerative and auto-immune indications, announced today thatPluristem's PLacenta eXpanded (PLX) cells have been demonstrated invitro to have properties that the Company believes gives thesecells th...

Human Genome Sciences Reports That a Phase 2 Study of LymphoStat-B Showed Significant Reductions in Disease Activity in Patients with Active Systemic Lupus Erythematosus

-LymphoStat-B(R) significantly reduced signs and symptoms of SLEdisease at 52 Weeks and demonstrated durable clinical andbiological activity at 76 weeks- ROCKVILLE, Md., June 14, 2007 /PRNewswire-FirstCall/ -- HumanGenome Sciences, Inc. today announced the presentation of Phase 2trial data demonstrating that LymphoStat-B(R) (belimumab)significantly reduced disease activity across multiple...

Research Indicates Geron's Human Embryonic Stem Cell-Based Therapeutic for Spinal Cord Injury Evades Direct Attack by the Human Immune System

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 11, 2007 - GeronCorporation (Nasdaq:GERN) today announced the presentation ofresearch studies indicating that GRNOPC1, the company's humanembryonic stem cell (hESC)-based therapeutic for the treatment ofspinal cord injury, evades a direct attack by the human immunesystem. Presented by Geron scientist Ross Okamura at the Federation ofClinical Immun...

Refrigerated Stem Cells Survive 12 Times Longer with ProtoKinetix's AAGP

VANCOUVER, British Columbia--(BUSINESS WIRE)--Jun 7, 2007 - As afollow up to ProtoKinetix Inc.'s (OTCBB:PKTX) May 23, 2007 pressrelease related to cryopreserved (or frozen) cells treated withAAGP(TM), in collaboration with the University of Helsinki,Finland, ProtoKinetix has recently finished a set of trialsdesigned to determine whether AAGP(TM) treated cells could surviveafter preservation...

Stanford Researchers Track Human Stem Cells Transplanted Into Rat Brain

STANFORD, Calif.--(BUSINESS WIRE)--Jun 4, 2007 - Researchers at theStanford University School of Medicine have illuminated the pathtaken by human neural stem cells that were transplanted into thebrains of rats and mice, and found that the cells successfullynavigate toward areas damaged by stroke. The research group placed miniscule particles of iron insidestem cells to act as cellular bea...

Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology

NATICK, Mass., June 04, 2007 /PRNewswire-FirstCall/ -- BostonScientific Corporation today welcomed the publication of an articlein the Journal of of Cardiology (JACC) reviewing the TAXUS ATLASclinical trial, which evaluates the Company's second-generationTAXUS(R) Liberte(TM)(1) paclitaxel-eluting stent system. Thearticle in the April 24 edition of JACC concluded that the shorterprocedure...

Daytrana (methylphenidate transdermal system) Provides Significant Effectiveness in ADHD Symptom Relief in Both Boys and Girls

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced today that DAYTRANA(TM) (methylphenidate transdermalsystem), its Attention Deficit Hyperactivity Disorder (ADHD) patch,had significant efficacy in reducing the symptoms of ADHD in bothmale and female children aged 6 to 12 years, according to clinicaltrial results reported at the American Psychiatric Association(APA) ann...

12-Month Study Demonstrated Tolerability and Efficacy of DAYTRANA (methylphenidate transdermal system)

SAN DIEGO, May 23, 2007 /PRNewswire-FirstCall/ -- Shire plcannounced that DAYTRANA(TM) (methylphenidate transdermal system),the first and only non-oral medication approved for treatment ofAttention Deficit Hyperactivity Disorder (ADHD) in children aged 6to 12 years, provided significant improvement in symptom controland tolerability, according to results of a 12-month open-labelstudy pre...

ProtoKinetix's AAGP Dramatically Increases Recovery Rate of Cryopreserved Stem Cells

VANCOUVER, British Columbia--(BUSINESS WIRE)--May 23, 2007 -ProtoKinetix Inc. (OTCBB:PKTX) has just received the results ofstudies conducted by ITTEC Stem, Inc. at the University of Finland.These outstanding results using AAGP(TM) in the cryopreservationprocess for stem cells demonstrate the vital importance of thismolecule in the rapidly expanding stem cell industry. This is thefirst serie...

SPIRIT Clinical Data Reaffirm Strength of Taxus and Promus Drug-Eluting Coronary Stent Systems

SPIRIT FIRST follow-up analysis shows no stent thrombosis or MACEafter one year NATICK, Mass. and BARCELONA, Spain, May 22, 2007/PRNewswire-FirstCall/ -- Boston Scientific Corporation todaywelcomed the results of additional data from the SPIRIT FIRST, IIand III Clinical Trials, reaffirming prior safety and efficacy datafor the market-leading TAXUS(R) Express2(TM) Paclitaxel-ElutingCorona...

Phase I/II-data on Systemic Application of the TGF-beta2-inhibitor AP 12009 to be Presented

REGENSBURG, Germany, May 10th, 2007 - AntisensePharma today announced, that the abstract entitled“Preliminary Results of a Phase I/II-Study in PancreaticCarcinoma, Malignant Melanoma, and Colorectal Carcinoma with theTGF-beta2 Inhibitor AP 12009” has been selected for posterpresentation at the 43rd Annual Meeting of the American Society ofClinical Oncology (ASCO)...

Conor Medsystems, LLC Reports COSTAR II Pivotal Drug-Eluting Stent Trial Conclusions

MENLO PARK, Calif., May 07, 2007 /PRNewswire-FirstCall/ --Citing issues related to potentially sub-optimal therapeutic dosingof paclitaxel, Conor Medsystems, LLC has concluded that the COSTARII (CObalt Chromium STent with Antiproliferative for Restenosis)trial, the pivotal study for the CoStar cobalt chromiumpaclitaxel-eluting coronary stent, failed to meet its primaryendpoint. The trial...

Pluristem to Present Two Scientific Posters at the International Society for Cellular Therapy

NEW YORK--(BUSINESS WIRE)--May 2, 2007 - Pluristem Life Systems,Inc. (OTCBB:PLRS), a cell therapy Company dedicated to thecommercialization of products for a variety of indications,announced today that it will present two scientific posters at the13th Annual Meeting of the International Society for CellularTherapy (ICST), June 24-27, 2007 in Sydney Australia. Pluristem CEO and Chairman, M...

Cellerant Therapeutics Reversed Autoimmune Disease in Lupus Mice with Transplant of Purified Donor Blood Stem Cells

SAN CARLOS, Calif.--(BUSINESS WIRE)--Apr 23, 2007 - CellerantTherapeutics today announced the publication of data suggestingthat established autoimmune disease can be reversed or stabilizedby the transplantation of purified allogeneic (donated)hematopoietic (blood forming) stem cells (HSC) in a mouse study ofSystemic Lupus Erythematosus (SLE). Subjects that underwent thisprocedure exhibited...

MedImmune Publishes New Data in Nature Immunology Demonstrating The Role HMGB1 May Play in Systemic Autoimmune Diseases

- Preclinical Data Support Rationale for Targeting Pro-InflammatoryProtein - GAITHERSBURG, Md., April 18, 2007 /PRNewswire-FirstCall/ --MedImmune, Inc. today announced the publication of preclinicalstudy data demonstrating a role for high mobility group boxprotein-1 (HMGB1), a nuclear DNA-binding protein, in the pathologyof systemic autoimmune diseases such as systemic lupuserythematosus...

ImClone Systems Showcases Extensive Research and Development Program at the AACR Annual Meeting

NEW YORK--(BUSINESS WIRE)--Apr 19, 2007 - IgG1 monoclonalantibodies developed by ImClone Systems Incorporated (NASDAQ: IMCL)were the focus of 44 total presentations at the recently concluded98th Annual Meeting of the American Association for Cancer Research(AACR), including seven oral presentations and 37 posters. Important ERBITUX(R) (cetuximab) clinical data were the focus oftwo back-to...

Calando Pharmaceuticals Announces Preclinical Efficacy and Safety Data of Targeted, Systemic Delivery of siRNA at AACR Annual Meeting

Data Indicate Significant Anti-Tumor Effects of Targeted, SystemicsiRNA Therapeutic at Doses Significantly Lower Than the Limits ofSafe Administrations in Rodent and Non-Human Primates PASADENA, Calif., April 16, 2007 /PRNewswire/ -- CalandoPharmaceuticals, a leading siRNA therapeutics company and amajority-owned subsidiary of Arrowhead Research Corporationpresented positive results of pr...

Arrowhead Subsidiaries Insert & Calando Present Data on Cyclosert Drug Delivery System at AACR Meeting

Novel Systems May Provide Cancer Patients With Improved Potentialto Battle Their Disease PASADENA, Calif., April 16, 2007 /PRNewswire-FirstCall/ --Arrowhead Research Corporation announced today that two of itsmajority-owned subsidiaries, Insert Therapeutics Inc. and CalandoPharmaceuticals Inc., are presenting data at the 2007 AmericanAssociation for Cancer Research (AACR) Annual Meeting....